collection
MENU ▼
Read by QxMD icon Read
search

Hjertesvigtsbehandling

shared collection
5 papers 0 to 25 followers
https://www.readbyqxmd.com/read/21073363/eplerenone-in-patients-with-systolic-heart-failure-and-mild-symptoms
#1
RANDOMIZED CONTROLLED TRIAL
Faiez Zannad, John J V McMurray, Henry Krum, Dirk J van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Stuart J Pocock, Bertram Pitt
BACKGROUND: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms. METHODS: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy...
January 6, 2011: New England Journal of Medicine
https://www.readbyqxmd.com/read/19723701/cardiac-resynchronization-therapy-for-the-prevention-of-heart-failure-events
#2
RANDOMIZED CONTROLLED TRIAL
Arthur J Moss, W Jackson Hall, David S Cannom, Helmut Klein, Mary W Brown, James P Daubert, N A Mark Estes, Elyse Foster, Henry Greenberg, Steven L Higgins, Marc A Pfeffer, Scott D Solomon, David Wilber, Wojciech Zareba
BACKGROUND: This trial was designed to determine whether cardiac-resynchronization therapy (CRT) with biventricular pacing would reduce the risk of death or heart-failure events in patients with mild cardiac symptoms, a reduced ejection fraction, and a wide QRS complex. METHODS: During a 4.5-year period, we enrolled and followed 1820 patients with ischemic or nonischemic cardiomyopathy, an ejection fraction of 30% or less, a QRS duration of 130 msec or more, and New York Heart Association class I or II symptoms...
October 1, 2009: New England Journal of Medicine
https://www.readbyqxmd.com/read/21366472/diuretic-strategies-in-patients-with-acute-decompensated-heart-failure
#3
RANDOMIZED CONTROLLED TRIAL
G Michael Felker, Kerry L Lee, David A Bull, Margaret M Redfield, Lynne W Stevenson, Steven R Goldsmith, Martin M LeWinter, Anita Deswal, Jean L Rouleau, Elizabeth O Ofili, Kevin J Anstrom, Adrian F Hernandez, Steven E McNulty, Eric J Velazquez, Abdallah G Kfoury, Horng H Chen, Michael M Givertz, Marc J Semigran, Bradley A Bart, Alice M Mascette, Eugene Braunwald, Christopher M O'Connor
BACKGROUND: Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS: In a prospective, double-blind, randomized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide administered intravenously by means of either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient's previous oral dose) or a high dose (2...
March 3, 2011: New England Journal of Medicine
https://www.readbyqxmd.com/read/20200382/comparison-of-dopamine-and-norepinephrine-in-the-treatment-of-shock
#4
RANDOMIZED CONTROLLED TRIAL
Daniel De Backer, Patrick Biston, Jacques Devriendt, Christian Madl, Didier Chochrad, Cesar Aldecoa, Alexandre Brasseur, Pierre Defrance, Philippe Gottignies, Jean-Louis Vincent
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0...
March 4, 2010: New England Journal of Medicine
https://www.readbyqxmd.com/read/23188026/associations-between-aldosterone-antagonist-therapy-and-risks-of-mortality-and-readmission-among-patients-with-heart-failure-and-reduced-ejection-fraction
#5
Adrian F Hernandez, Xiaojuan Mi, Bradley G Hammill, Stephen C Hammill, Paul A Heidenreich, Frederick A Masoudi, Laura G Qualls, Eric D Peterson, Gregg C Fonarow, Lesley H Curtis
CONTEXT: Aldosterone antagonist therapy for heart failure and reduced ejection fraction has been highly efficacious in randomized trials. However, questions remain regarding the effectiveness and safety of the therapy in clinical practice. OBJECTIVE: To examine the clinical effectiveness of newly initiated aldosterone antagonist therapy among older patients hospitalized with heart failure and reduced ejection fraction. DESIGN, SETTING, AND PARTICIPANTS: Using clinical registry data linked to Medicare claims from 2005 through 2010, we examined outcomes of eligible patients hospitalized with heart failure and reduced ejection fraction...
November 28, 2012: JAMA: the Journal of the American Medical Association
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"